Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
0.8100
-0.0100 (-1.22%)
Mar 12, 2026, 4:00 PM EDT - Market closed
Immuron Revenue
In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M AUD with 48.63% growth. Immuron had revenue of 1.27M in the half year ending June 30, 2024, with 108.61% growth.
Revenue (ttm)
7.29M AUD
Revenue Growth
+170.82%
P/S Ratio
1.44
Revenue / Employee
1,041,000 AUD
Employees
7
Market Cap
7.18M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.37M | -94.21% |
| Jun 30, 2020 | 2.52M | 131.14K | 5.49% |
| Jun 30, 2019 | 2.39M | 544.52K | 29.55% |
| Jun 30, 2018 | 1.84M | 446.71K | 31.99% |
| Jun 30, 2017 | 1.40M | 395.12K | 39.47% |
| Jun 30, 2016 | 1.00M | -1.30K | -0.13% |
| Jun 30, 2015 | 1.00M | 21.33K | 2.17% |
| Jun 30, 2014 | 981.05K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 3.85M |
| XTL Biopharmaceuticals | 968.00K |
| BioRestorative Therapies | 383.40K |
| Addex Therapeutics | 198.82K |
| Creative Medical Technology Holdings | 6.00K |
| Alaunos Therapeutics | 6.00K |
IMRN News
- 7 days ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 7 days ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 7 weeks ago - Immuron Limited (IMRN) Presents at Emerging Growth Conference 89 - Slideshow - Seeking Alpha
- 7 weeks ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 7 weeks ago - Immuron Reports Continued Sales Growth - GlobeNewsWire
- 3 months ago - Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes - GuruFocus
- 4 months ago - Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529 - GuruFocus
- 4 months ago - Immuron: FDA Approves IND Application For IMM-529 - Nasdaq